Core Insights - Southbound funds increased their holdings in Baize Medical (02609.HK) by 384,600 shares on October 15, 2025, marking a net increase of 2,892,600 shares over the last five trading days [1] - Over the past 20 trading days, Baize Medical has seen a total net increase of 67,140,600 shares from southbound funds, with 16 days of net buying activity [1] - As of now, southbound funds hold 67,140,600 shares of Baize Medical, representing 5.08% of the company's total issued ordinary shares [1] Trading Data Summary - On October 15, 2025, total shares held reached 67,140,600 with a change of 384,600 shares, reflecting a 0.58% increase [2] - On October 14, 2025, total shares held were 66,756,000 with a change of 180,000 shares, a 0.27% increase [2] - On October 13, 2025, total shares held were 66,576,000 with a change of 897,600 shares, a 1.37% increase [2] - On October 3, 2025, total shares held were 65,678,400 with a change of 1,597,200 shares, a 2.49% increase [2] - On October 2, 2025, total shares held were 64,081,200 with a change of -166,800 shares, a -0.26% decrease [2] Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [2] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [2] - Key business areas include hospital operations, hospital management services, supply of pharmaceuticals, medical devices, and consumables [2] - Services provided encompass cancer diagnosis, treatment, rehabilitation, and end-of-life care, as well as early cancer screening, cancer vaccination, and health management for other potential health populations [2] - The company primarily operates in the Chinese market [2]
佰泽医疗（02609.HK）：10月15日南向资金增持38.46万股